Using AI to find new treatments for substance use disorders
AI Platform to Discover Therapeutics for Substance Use Disorders
This study is exploring how artificial intelligence can help find new treatments for substance use disorders by looking at specific pathways in the body that might help reduce cravings for things like opioids, nicotine, and alcohol, so that patients can have better options for recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Callentis Consulting Group LLC NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11144833 on NIH RePORTER |
What this research studies
This research aims to tackle substance use disorders (SUDs) by utilizing artificial intelligence (AI) to identify and validate potential treatment targets. The approach involves creating curated datasets and machine learning models to accelerate drug discovery processes. By focusing on the glucagon-like peptide 1 (GLP-1) pathways, the research seeks to understand how these pathways can reduce cravings for addictive substances like opiates, nicotine, and alcohol. Patients may benefit from new therapeutic options that emerge from this innovative AI-driven methodology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from substance use disorders, including those addicted to alcohol, nicotine, or opioids.
Not a fit: Patients who do not have substance use disorders or those who are not seeking treatment for addiction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective new treatments for individuals struggling with substance use disorders.
How similar studies have performed: Other research has shown promise in using AI for drug discovery, particularly in targeting complex conditions like addiction, suggesting that this approach could yield significant advancements.
Where this research is happening
Austin, United States
- Callentis Consulting Group LLC — Austin, United States (Active)
Researchers
- Principal investigator: Lauver, Dale Adam — Callentis Consulting Group LLC
- Study coordinator: Lauver, Dale Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.